Cartesian Therapeutics, Inc. — Director's Dealing 2025

Apr 11, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2025-04-09

Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-04-09	Common Stock	P	7342	$9.4264	Acquired	8628667	Direct
2025-04-09	Common Stock	P	31	$9.9509	Acquired	8628698	Direct
2025-04-09	Common Stock	P	41604	$9.4264	Acquired	571402	Indirect
2025-04-09	Common Stock	P	178	$9.9509	Acquired	571580	Indirect
2025-04-10	Common Stock	P	7966	$10.4345	Acquired	8636664	Direct
2025-04-10	Common Stock	P	609	$10.9231	Acquired	8637273	Direct
2025-04-10	Common Stock	P	45144	$10.4345	Acquired	616724	Indirect
2025-04-10	Common Stock	P	3451	$10.9231	Acquired	620175	Indirect
2025-04-11	Common Stock	P	6412	$10.7726	Acquired	8643685	Direct
2025-04-11	Common Stock	P	36338	$10.7726	Acquired	656513	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	330695	Indirect

Footnotes

F1: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $8.95 to $9.91. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.95 to $9.97. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F3: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.

F4: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.918 to $10.7461. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F5: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $10.395 to $11.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.